• Jean Paul Bouwyn, Patrick Magnier, Anne-Laure Bédat-Millet, Patrick Ahtoy, David Maltête, and Romain Lefaucheur.
• Department of Neurology, Rouen University Hospital and University of Rouen, France.
• Neuromuscul. Disord. 2016 Jul 1; 26 (7): 453-4.

AbstractMyasthenia gravis (MG) with antibodies against muscle-specific tyrosine kinase (MuSK) is a rare disorder of neuromuscular transmission affecting preferentially bulbar, neck and respiratory muscles. We report the case of a 22-year-old man who presented with diplopia on lateral gaze to both sides, facial diplegia, nasal dysarthria and dysphagia. Repetitive nerve stimulation of the trapezius and orbicularis oculi muscles showed amplitude decrements of 19% and 41% respectively supporting the diagnosis of myasthenia gravis. MUsK antibodies were positive. Corticosteroids were introduced and then tapered and discontinued at 6 months after initiation. The patient remained in remission and asymptomatic for 4 years without ongoing treatment or prior treatment with rituximab after this first relapse of MuSK-MG. MuSK- MG is considered a hard-to-treat condition and patients generally remain dependent on immunosuppression or prior treatment with rituximab. Our observation highlights that patients with MuSK-MG can have a benign course and that continued immunosuppressive or immunomodulatory therapy may not always be required.Copyright © 2016 Elsevier B.V. All rights reserved.

20 keywords...

hide…